Description
SWOT ANALYSIS OF CIPLA
Cipla
Parent Company
Cipla
Category
Pharmaceuticals
Sector
Healthcare Industry
Tagline/ Slogan
Caring for life
Commitment to make medicines affordable and accessible particularly USP to cancer patients
STP
Segment
AIDS, respiratory disease, cancer cardiovascular disease, arthritis
Customers of various flavors and fragrances, OTC products, Target Group prescription products, pesticides, agrochemicals, doctors
They use latest technology to concentrate all their knowledge of over Positioning seven decades in developing life saving drugs
SWOT Analysis
1. Cipla has developed good positive image by providing support to cancer patients by issuing drugs at low cost 2. Imminent commencement of the Fixed-Dose combination for treatment of uncomplicated P. falciparum malaria to tackle the 200+ million cases of malaria globally 3. Initiation of ‘No Touch Breast Scan’ a step forward in the screening technology in India. 4. A foremost player in anti-infective and anti-asthmatic formulations. Strength 5. Has a strong employee force of over 16,000
1. Strong competition from international and domestic giants means limited market share Weakness 2. Cipla had faced problems during negative campaign by AHF
1. It can venture into Alzheimer’s disease medication 2. They can use Viramune generic to achieve higher growth. 3. Increased investment in the budding markets, to push expansion in Opportunity the global economy
1. Constant price rises in the Indian country is taking its toll and compounding the problem 2.The Indian Rupee depreciated as compared to the US Dollar 3. Fluctuations in currency exchange rates have a noteworthy impact Threats on the Company’s operations and financial results.
Competition
1. Sun Pharmaceuticals 2. Dr. Reddy’s laboratories 3. Lupin Competitors 4. Ranbaxy labs
doc_345481612.docx
SWOT ANALYSIS OF CIPLA
Cipla
Parent Company
Cipla
Category
Pharmaceuticals
Sector
Healthcare Industry
Tagline/ Slogan
Caring for life
Commitment to make medicines affordable and accessible particularly USP to cancer patients
STP
Segment
AIDS, respiratory disease, cancer cardiovascular disease, arthritis
Customers of various flavors and fragrances, OTC products, Target Group prescription products, pesticides, agrochemicals, doctors
They use latest technology to concentrate all their knowledge of over Positioning seven decades in developing life saving drugs
SWOT Analysis
1. Cipla has developed good positive image by providing support to cancer patients by issuing drugs at low cost 2. Imminent commencement of the Fixed-Dose combination for treatment of uncomplicated P. falciparum malaria to tackle the 200+ million cases of malaria globally 3. Initiation of ‘No Touch Breast Scan’ a step forward in the screening technology in India. 4. A foremost player in anti-infective and anti-asthmatic formulations. Strength 5. Has a strong employee force of over 16,000
1. Strong competition from international and domestic giants means limited market share Weakness 2. Cipla had faced problems during negative campaign by AHF
1. It can venture into Alzheimer’s disease medication 2. They can use Viramune generic to achieve higher growth. 3. Increased investment in the budding markets, to push expansion in Opportunity the global economy
1. Constant price rises in the Indian country is taking its toll and compounding the problem 2.The Indian Rupee depreciated as compared to the US Dollar 3. Fluctuations in currency exchange rates have a noteworthy impact Threats on the Company’s operations and financial results.
Competition
1. Sun Pharmaceuticals 2. Dr. Reddy’s laboratories 3. Lupin Competitors 4. Ranbaxy labs
doc_345481612.docx